Active Not RecruitingNCT05824728
AGB101 or placebo for psychosis in Parkinson’s disease
About this title
Read the official source — NCT05824728Medication studyAges 40–85United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 40 years to 85 years.
- Listed locations
- BaltimoreSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 28, 2023
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- Johns Hopkins University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 40 Years to 85 Years
- Official registry ID
- NCT05824728
- Official title
Show the full official title
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Baltimore
Questions about this study
Who is behind this study?
The study sponsor is Johns Hopkins University, a university.
Does this study involve medication?
Yes. The study involves medication, including AGB101.
Who can participate?
Listed age limits: 40 years to 85 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
